D. E. Shaw & Co. Inc. increased its stake in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 12.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 295,717 shares of the company's stock after acquiring an additional 32,062 shares during the quarter. D. E. Shaw & Co. Inc. owned approximately 1.61% of OptimizeRx worth $1,437,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also bought and sold shares of OPRX. SBI Securities Co. Ltd. bought a new position in shares of OptimizeRx in the fourth quarter worth approximately $25,000. SG Americas Securities LLC bought a new position in OptimizeRx during the 4th quarter valued at approximately $51,000. Wells Fargo & Company MN increased its holdings in shares of OptimizeRx by 33.3% during the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock valued at $54,000 after acquiring an additional 2,797 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in shares of OptimizeRx by 504.6% in the fourth quarter. BNP Paribas Financial Markets now owns 22,308 shares of the company's stock worth $108,000 after buying an additional 18,618 shares in the last quarter. Finally, Corton Capital Inc. bought a new stake in shares of OptimizeRx during the fourth quarter valued at approximately $110,000. 76.47% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
OPRX has been the subject of a number of research analyst reports. Citigroup reiterated an "outperform" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. JMP Securities increased their target price on OptimizeRx from $11.00 to $14.00 and gave the company a "market outperform" rating in a report on Tuesday, May 13th. Wall Street Zen raised OptimizeRx from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Stifel Nicolaus lifted their price target on shares of OptimizeRx from $8.00 to $12.50 and gave the company a "buy" rating in a report on Tuesday, May 13th. Finally, Roth Capital restated a "buy" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $10.38.
Get Our Latest Stock Analysis on OPRX
Insider Transactions at OptimizeRx
In other news, Director James Paul Lang purchased 321,408 shares of the business's stock in a transaction on Friday, March 14th. The shares were acquired at an average cost of $7.60 per share, with a total value of $2,442,700.80. Following the completion of the acquisition, the director now owns 389,452 shares of the company's stock, valued at $2,959,835.20. This trade represents a 472.35% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 5.60% of the company's stock.
OptimizeRx Trading Down 4.2%
Shares of OPRX traded down $0.53 during mid-day trading on Wednesday, reaching $12.11. 26,103 shares of the company's stock traded hands, compared to its average volume of 414,454. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23. The stock's 50-day moving average is $9.29 and its two-hundred day moving average is $6.79. OptimizeRx Co. has a 12 month low of $3.78 and a 12 month high of $12.78. The stock has a market cap of $223.97 million, a P/E ratio of -9.11 and a beta of 1.28.
OptimizeRx (NASDAQ:OPRX - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.11) by $0.19. The company had revenue of $21.93 million for the quarter, compared to the consensus estimate of $18.69 million. OptimizeRx had a negative net margin of 27.41% and a negative return on equity of 4.92%. Research analysts forecast that OptimizeRx Co. will post -0.33 earnings per share for the current fiscal year.
About OptimizeRx
(
Free Report)
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.
Further Reading
Before you consider OptimizeRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptimizeRx wasn't on the list.
While OptimizeRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
